<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-276 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-276</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-276</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-1e703a2c4f1b4559486ff0082602089ea163287e</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/1e703a2c4f1b4559486ff0082602089ea163287e" target="_blank">Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer.</a></p>
                <p><strong>Paper Venue:</strong> Revista Portuguesa de Pneumologia</p>
                <p><strong>Paper TL;DR:</strong> A better understanding of the EGFR mutation rate in the Portuguese population is permitted as well as an evaluation of the patients survival after the use of of tyrosine kinase inhibitors, in second and third line therapy with previous knowledge of the EGFR mutational status.</p>
                <p><strong>Cost:</strong> 0.009</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e276.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e276.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Portuguese 5yr EGFR study</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal Growth Factor Receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-center Portuguese cohort (2006–2010) of 374 NSCLC patients undergoing EGFR exon 18–21 sequencing, reporting overall mutation frequency, exon distribution, and clinical correlates (sex, smoking, histology) and survival after TKI therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal Growth Factor Receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>374 consecutive patients tested for EGFR mutations at Centro Hospitalar Vila Nova de Gaia-Espinho, Portugal (2006–2010). Geographic location: Portugal; ethnicity/ancestry not explicitly stated (presumed predominantly Portuguese/Caucasian). Patient characteristics: 71.1% male, mean age 64.5 ± 11.3 years; smoking status overall: 31.3% never-smokers, 35.8% ex-smokers, 32.9% current smokers; histology: 57.8% adenocarcinoma, 23.5% squamous cell carcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td>Reported exon distribution among mutated tumors: exon 18 = 10.2% of mutations; exon 19 = 38.8% (including deletions); exon 20 = 18.4% (6.2% were resistance-associated, e.g., T790M); exon 21 = 32.7% (includes L858R). Specific types discussed include exon 19 deletions and L858R (exon 21), Gly719 (exon 18) and exon 20 insertions/resistance (e.g., T790M) in background text.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td>This Portuguese cohort: 13.1% overall (49/374). Subgroups: 9% in males vs 23% in females; selected patients (2006–2009) 16.3% vs unselected 2010 cohort 10.4%. The paper cites European literature prevalence ~10–15% and Spain (Rosell et al.) 16.6% in a selected advanced group.</td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td>Among mutated patients (n=49): 46.9% were never-smokers, 30.6% ex-smokers, 22.4% current smokers. By sex: mutated females (n=25) — 88% never-smokers; mutated males (n=24) — 91.7% were current or ex-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>EGFR mutations predominated in adenocarcinoma: overall cohort adenocarcinoma 57.8%; among mutated patients 59.2% adenocarcinoma. Mutated females: 80% adenocarcinoma; mutated males: higher proportion of squamous cell carcinoma (45.8%) noted in mutated men in this sample.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>The paper discusses smoking status as a clinical correlate but does not identify or propose other environmental factors (e.g., air pollution, cooking fumes, occupational exposures) as explanations for ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>No specific genetic/ancestral or germline factors are proposed or analyzed in this study to explain ethnic differences; the paper only cites literature identifying 'ethnicity (Asian)' as a clinical predictor of mutation but provides no mechanistic genetic data.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>The paper does not propose a biological, molecular, or evolutionary mechanism to explain higher EGFR mutation prevalence in Asian populations; it only cites prior literature noting Asian ethnicity as associated with higher mutation prevalence/response.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Authors note selection bias: different inclusion criteria across years (2006–2009 selected patients: histology adenocarcinoma and never/ex-smokers giving higher observed mutation rate [16.3%] vs 2010 unselected cohort 10.4%). They also note lack of a reliable national lung-cancer registry in Portugal, potential referral/selection biases, and limited sample sizes for some subgroup comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>Overall EGFR mutation frequency in this Portuguese cohort was 13.1% (49/374), with strong enrichment in females (23% vs 9% in males), never-smokers (46.9% of mutated patients were never-smokers), and adenocarcinoma histology (59.2% of mutated cases). Exon distribution among mutations: exon19 (38.8%) and exon21 (32.7%) most common. The paper acknowledges literature reports of higher EGFR mutation prevalence in Asian patients but does not present direct ethnic comparisons or mechanistic explanations; it emphasizes the effect of selection criteria on observed prevalence.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Screening for epidermal growth factor receptor mutations in lung cancer <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 2)</em></li>
                <li>EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>